Details for New Drug Application (NDA): 201689
✉ Email this page to a colleague
NDA 201689 describes IFOSFAMIDE, which is a drug marketed by Fresenius Kabi Usa, Hikma, Meitheal, Rising, and Teva Pharms Usa, and is included in six NDAs. It is available from two suppliers. Additional details are available on the IFOSFAMIDE profile page.
The generic ingredient in IFOSFAMIDE is ifosfamide; mesna. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ifosfamide; mesna profile page.
The generic ingredient in IFOSFAMIDE is ifosfamide; mesna. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ifosfamide; mesna profile page.
Summary for 201689
| Tradename: | IFOSFAMIDE |
| Applicant: | Rising |
| Ingredient: | ifosfamide |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 201689
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 1GM/20ML (50MG/ML) | ||||
| Approval Date: | Nov 26, 2012 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 3GM/60ML (50MG/ML) | ||||
| Approval Date: | Nov 26, 2012 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
